Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Wild Type p53 Adenovirus for Oral Premalignancies

This study has been terminated.
(Sponsor withdrawl prior to study completion.)
National Cancer Institute (NCI)
Department of Health and Human Services
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: December 11, 2006
Last updated: December 6, 2011
Last verified: December 2011

Primary Objectives:

  1. To determine the maximum tolerated dose and transduction efficiency of adenoviral mediated wild type p53 gene transfer in premalignancies of the upper aerodigestive tract.
  2. To determine the efficacy of single agent adenoviral mediated wild type p53 gene transfer in reversing oral premalignancies.

Condition Intervention Phase
Mouth Cancer
Genetic: INGN 201
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]

Resource links provided by NLM:

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) of INGN 201 [ Time Frame: Following 1 week of experimental treatment in each 4 week course ]
    MTD is defined as the highest dose level at which there are less than or equal to 1/6 patients with a dose limiting toxicity (DLT).

Enrollment: 4
Study Start Date: June 2003
Study Completion Date: November 2010
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: INGN 201
INGN201 injection + oral rinse, day 1, courses 1-6. Twice-daily oral rinses, days 2-5, courses 1-6.
Genetic: INGN 201
Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
Other Names:
  • Advexin
  • Ad-p53

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, aged 18 years and older.
  • Patients must have histologically confirmed diagnosis of mild-moderate dysplasia or severe dysplasia/carcinoma in situ (CIS) of the oral cavity or oral pharynx.
  • Patients must have clinical evidence of mild to moderate dysplasia or severe dysplasia/CIS of the oral cavity or oral pharynx that is diffuse.
  • Patients must have diffuse* premalignant disease of the oral cavity or oral pharynx and must have: a) been previously treated with conventional treatment (e.g.: radiation or surgery) for a prior head & neck malignancy or b) failed biochemoprevention approaches for premalignant disease or c) failed other therapeutic approaches for premalignant disease. (*See protocol for definition of diffuse.)
  • All patients must have a Karnofsky performance status of greater than or equal to 70% (Karnofsky scale, Appendix B).
  • All patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the institution.
  • If female and of childbearing potential (non-childbearing defined as 1 year post menopause or surgically sterilized), patients must have a negative serum pregnancy test. Patients (male and female) must agree to use barrier contraception while on study and to avoid pregnancy for 1 year after treatment.
  • Patients must have negative serology for the Human Immunodeficiency Virus (HIV) Type I. (Safety of the product has not been established or studied in immunosuppressed populations).
  • Patients must have adequate bone marrow function (defined as peripheral absolute granulocyte count of greater than or equal to 2,000/ul and platelet count of greater than or equal to 100,000/ul), adequate liver function (bilirubin less than or equal to 1.0 mg/dl), and adequate renal function (creatinine less than or equal to 1.5 mg/dl).
  • Patients must not knowingly be in contact with former tissue or organ transplant recipients and persons known to them to be suffering from severe immunodeficiency disease (either acquired or congenital) during treatment or within 28 days following the last dosing with Ad5CMV p53 (INGN 201).

Exclusion Criteria:

  • Active squamous cell carcinoma of the head and neck.
  • History of prior malignancies (excluding non-melanoma skin cancers and aerodigestive cancers) unless curatively treated and disease free for greater than or equal to 2 years.
  • Prior experimental therapy oral, systemic, topical, or directly injected into the lesion selected for treatment in this study, or radiation directly involving the lesion selected in the last three (3) months.
  • Chemotherapy within 21 days prior to study (42 days for mitomycin C and nitrosoureas).
  • Pregnant or lactating females. (Transplacental transfer and excretion in breast milk have not been studied with this agent).
  • Active systemic viral, bacterial, or fungal infections requiring treatment.
  • Patients with serious concurrent illness of psychological, familial, sociological, geographical or other concomitant conditions which do not allow for adequate follow up and compliance with the study protocol.
  • Concurrent use of other investigational agents.
  • Prior use of any other investigational agent requires a washout period of 8 weeks.
  • Any immunosuppressive therapy (including corticosteroids > 10 mg/day) of prednisone or the equivalent.
  • Aspirin use in an average dose of >175 mg/d.
  • Patients evaluated by Internal Medicine with a baseline blood pressure of > or equal to 140/90 and deemed hypertensive.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00410865

United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Department of Health and Human Services
Principal Investigator: Gary L. Clayman, MD U.T. MD Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00410865     History of Changes
Other Study ID Numbers: ID00-193
Study First Received: December 11, 2006
Last Updated: December 6, 2011

Keywords provided by M.D. Anderson Cancer Center:
Oral Premalignancies
Mouth Cancer
Dysplasia/Carcinoma in Situ (CIS) of the Oral Cavity
Dysplasia/Carcinoma in situ (CIS) of the Oral Pharynx
Gene Therapy
INGN 201
Wild Type p53 Gene Induction

Additional relevant MeSH terms:
Mouth Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Mouth Diseases
Stomatognathic Diseases processed this record on April 21, 2017